vs
Side-by-side financial comparison of Prestige Consumer Healthcare Inc. (PBH) and QUHUO Ltd (QH). Click either name above to swap in a different company.
Prestige Consumer Healthcare Inc. is the larger business by last-quarter revenue ($283.4M vs $157.9M, roughly 1.8× QUHUO Ltd).
Prestige Consumer Healthcare Inc. is an American company that markets and distributes over-the-counter healthcare and household cleaning products. It was formed by the merger of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company in 1996. The company is headquartered in Tarrytown, New York and operates a manufacturing facility in Lynchburg, Virginia.
QUHUO Ltd. operates an on-demand lifestyle service platform focused on the Chinese mainland market. Its core offerings include gig workforce solutions, community group-buy services, and local life service matching for merchants and individual users, covering household services, catering operation support, and community retail segments to effectively connect service providers with end consumers.
PBH vs QH — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $283.4M | $157.9M |
| Net Profit | $46.7M | — |
| Gross Margin | 55.5% | — |
| Operating Margin | 29.1% | — |
| Net Margin | 16.5% | — |
| Revenue YoY | -2.4% | — |
| Net Profit YoY | -23.5% | — |
| EPS (diluted) | $0.97 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $283.4M | — | ||
| Q3 25 | $274.1M | — | ||
| Q2 25 | $249.5M | $157.9M | ||
| Q1 25 | $296.5M | — | ||
| Q4 24 | $290.3M | — | ||
| Q3 24 | $283.8M | — | ||
| Q2 24 | $267.1M | $222.9M | ||
| Q1 24 | $277.0M | — |
| Q4 25 | $46.7M | — | ||
| Q3 25 | $42.2M | — | ||
| Q2 25 | $47.5M | — | ||
| Q1 25 | $50.1M | — | ||
| Q4 24 | $61.0M | — | ||
| Q3 24 | $54.4M | — | ||
| Q2 24 | $49.1M | $-6.4M | ||
| Q1 24 | $49.5M | — |
| Q4 25 | 55.5% | — | ||
| Q3 25 | 55.3% | — | ||
| Q2 25 | 56.2% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 55.5% | — | ||
| Q2 24 | 54.7% | 1.5% | ||
| Q1 24 | 54.8% | — |
| Q4 25 | 29.1% | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 28.8% | — | ||
| Q1 25 | 29.8% | — | ||
| Q4 24 | 31.7% | — | ||
| Q3 24 | 29.7% | — | ||
| Q2 24 | 27.0% | -2.7% | ||
| Q1 24 | 29.7% | — |
| Q4 25 | 16.5% | — | ||
| Q3 25 | 15.4% | — | ||
| Q2 25 | 19.0% | — | ||
| Q1 25 | 16.9% | — | ||
| Q4 24 | 21.0% | — | ||
| Q3 24 | 19.2% | — | ||
| Q2 24 | 18.4% | -2.9% | ||
| Q1 24 | 17.9% | — |
| Q4 25 | $0.97 | — | ||
| Q3 25 | $0.86 | — | ||
| Q2 25 | $0.95 | — | ||
| Q1 25 | $1.00 | — | ||
| Q4 24 | $1.22 | — | ||
| Q3 24 | $1.09 | — | ||
| Q2 24 | $0.98 | — | ||
| Q1 24 | $0.98 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $62.4M | $4.3M |
| Total DebtLower is stronger | $1.0B | $858.0K |
| Stockholders' EquityBook value | $1.8B | $57.4M |
| Total Assets | $3.5B | $118.4M |
| Debt / EquityLower = less leverage | 0.56× | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $62.4M | — | ||
| Q3 25 | $119.1M | — | ||
| Q2 25 | $139.5M | $4.3M | ||
| Q1 25 | $97.9M | — | ||
| Q4 24 | $50.9M | — | ||
| Q3 24 | $51.5M | — | ||
| Q2 24 | $34.3M | $14.3M | ||
| Q1 24 | $46.5M | — |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | $858.0K | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | $1.2M | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.9B | $57.4M | ||
| Q1 25 | $1.8B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | $64.6M | ||
| Q1 24 | $1.7B | — |
| Q4 25 | $3.5B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.4B | $118.4M | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $3.3B | — | ||
| Q2 24 | $3.3B | $135.0M | ||
| Q1 24 | $3.3B | — |
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | 0.01× | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | 0.02× | ||
| Q1 24 | 0.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $78.3M | $-5.8M |
| Free Cash FlowOCF − Capex | $75.3M | — |
| FCF MarginFCF / Revenue | 26.6% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | 1.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | $267.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $78.3M | — | ||
| Q3 25 | $57.5M | — | ||
| Q2 25 | $79.0M | $-5.8M | ||
| Q1 25 | $61.8M | — | ||
| Q4 24 | $65.1M | — | ||
| Q3 24 | $69.8M | — | ||
| Q2 24 | $54.8M | — | ||
| Q1 24 | $66.9M | — |
| Q4 25 | $75.3M | — | ||
| Q3 25 | $55.4M | — | ||
| Q2 25 | $78.2M | — | ||
| Q1 25 | $58.4M | — | ||
| Q4 24 | $63.5M | — | ||
| Q3 24 | $67.8M | — | ||
| Q2 24 | $53.6M | — | ||
| Q1 24 | $63.8M | — |
| Q4 25 | 26.6% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 19.7% | — | ||
| Q4 24 | 21.9% | — | ||
| Q3 24 | 23.9% | — | ||
| Q2 24 | 20.1% | — | ||
| Q1 24 | 23.0% | — |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.66× | — | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.12× | — | ||
| Q1 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
QH
Segment breakdown not available.
